The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

Description

Obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with obesity as well as potential mechanisms to modify disease.

Conditions

Type 1 Diabetes, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

Obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with obesity as well as potential mechanisms to modify disease.

The Gut Microbiome in Lean and Overweight Youth With Type 1 Diabetes and Novel Mechanism of Action of Metformin

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

Condition
Type 1 Diabetes
Intervention / Treatment

-

Contacts and Locations

Indianapolis

Indiana University School of Medicine, Indianapolis, Indiana, United States, 46202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Obese youth 11-18 years of age with T1D at time of enrollment.
  • 2. Lean youth 11-18 years of age with T1D at time of enrollment.
  • 1. Known monogenic forms of diabetes or Type 2 diabetes (confirmed clinically and by genetic/antibody testing).
  • 2. History of ongoing infection or antibiotic treatment within the past month;
  • 3. History of immune-compromise, recurrent infections, steroid intake (inhaled or oral forms) or other immunosuppressant use in the past 6 months.
  • 4. History of chronic gastrointestinal disease, possible or confirmed celiac disease;
  • 5. Participation in any research intervention trials within the past 3 months.
  • 6. History of treatment or use of metformin, a type 2 diabetes medication.

Ages Eligible for Study

11 Years to 18 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Heba M. Ismail,

Study Record Dates

2026-08-01